Skip to main content

Advertisement

Table 5 Multivariate analysis for the predictive value of PTEN deletion, MGMT methylation and EGFR amplification in GBM IDH wildtype

From: Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

  Median Survival (MS-months) N Multivariate analysisa
Hazard ratio 95% Cl p-Value
GBM IDH-wildtype
CRT 16.0 104 0.053 0.029–0.098 < 0.001
RT 6.0 104 0.181 0.105–0.314 < 0.001
None 2.0 18   Reference  
RT
PTEN
  Deleted 7.0 74 0.74 0.45–1.24 0.258
  Non-deleted 6.0 20   Reference  
MGMT
  Methylated 7.0 24 1.09 0.67–1.78 0.733
  Unmethylated 6.0 70   Reference  
EGFR
  Amplified 9.0 39 0.56 0.36–0.88 0.011
  Non-amplified 6.0 55   Reference  
CRT
PTEN
  Deleted 14.0 84 1.68 0.40–7.15 0.481
  Non-deleted 14.0 5   Reference  
MGMT
  Methylated 32.0 20 0.34 0.17–0.69 0.003
  Unmethylated 14.0 69   Reference  
EGFR
  Amplified 15.0 32 0.88 0.54–1.43 0.596
  Non-amplified 14.0 57   Reference  
  1. aMultivariate analysis was performed controlling the following independent variables: age and gender. RT Radiotherapy, CRT Chemo-radiotherapy